J Cancer 2021; 12(9):2560-2569. doi:10.7150/jca.55322 This issue Cite

Research Paper

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G

Paul Zarogoulidis1✉, Wolfgang Hohenforst-Schmidt2, Haidong Huang3*, Jun Zhou4*, Qin Wang3*, Xiangqi Wang3*, Ying Xia3*, Yinfeng Ding3*, Chong Bai3✉*, Christoforos Kosmidis1, Konstantinos Sapalidis1, Chrysanthi Sardeli4, Kosmas Tsakiridis5, Bojan Zaric6, Tomi Kovacevic6, Vladimir Stojsic6, Tatjana Sarcev6, Daliborka Bursac6, Biljana Kukic6, Sofia Baka7, Evagelia Athanasiou8, Dimitrios Hatzibougias8, Electra Michalopoulou-Manoloutsiou8, Savvas Petanidis9, Dimitris Drougas10, Konstantinos Drevelegas11, Dimitris Paliouras12, Nikolaos Barbetakis12, Anastasios Vagionas13, Lutz Freitag14, Aimilios Lallas15, Ioannis Boukovinas16, Dimitris Petridis17, Aris Ioannidis18, Dimitris Matthaios19, Konstantinos Romanidis20, Chrisanthi Karapantzou21

1. 3rd Department of Surgery, ``AHEPA`` University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
2. Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, ''Hof'' Clinics, University of Erlangen, Hof, Germany.
3. Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Naval Medical University ( Changhai Hospital, Second Military Medical University), Shanghai, China.
4. Department of Respiratory, Changzhou maternal and child health care hospital affiliated to Nanjing Medical University, Jiangsu Changzhou, China.
5. Thoracic Surgery Department, ``Interbalkan`` European Medical Center, Thessaloniki, Greece.
6. Faculty of Medicine, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina, Novi Sad, Serbia.
7. Oncology Department, ``Interbalkan`` European Medical Center, Thessaloniki, Greece.
8. Private Pathology Laboratory, "Microdiagnostics", Thessaloniki, Greece.
9. Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
10. Scientigraphy Department, "Bioclinic" Private Laboratory, Thessaloniki, Greece.
11. Radiology Department, "Euromedica" Private Radiology Laboratory, Thessaloniki, Greece.
12. Thoracic surgery Department, ``Theageneio`` Cancer Hospital, Thessaloniki, Greece.
13. Oncology Department, General Hospital of Kavala, Kavala, Greece.
14. Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich Switzerland.
15. Dermatology Department, Aristotle University, School of Medicine, Thessaloniki, Greece.
16. Oncology Department, ``Bioclinic`` Private Hospital, Thessaloniki, Greece.
17. Department of Food Science and Technology, International Hellenic University, Thessaloniki, Greece.
18. Surgery Department, ``Genesis`` Private Hospital, Thessaloniki, Greece.
19. Oncology Department, General Hospital of Rhodes, Greece.
20. Department of Surgery, University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
21. Ear, Nose and Throat (ENT) Department, Ludwig-Maximilians University of Munich, Munich, Germany.
* These authors contributed equally.

Citation:
Zarogoulidis P, Hohenforst-Schmidt W, Huang H, Zhou J, Wang Q, Wang X, Xia Y, Ding Y, Bai C, Kosmidis C, Sapalidis K, Sardeli C, Tsakiridis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Baka S, Athanasiou E, Hatzibougias D, Michalopoulou-Manoloutsiou E, Petanidis S, Drougas D, Drevelegas K, Paliouras D, Barbetakis N, Vagionas A, Freitag L, Lallas A, Boukovinas I, Petridis D, Ioannidis A, Matthaios D, Romanidis K, Karapantzou C. Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G. J Cancer 2021; 12(9):2560-2569. doi:10.7150/jca.55322. https://www.jcancer.org/v12p2560.htm
Other styles

File import instruction

Abstract

Graphic abstract

Introduction: Immunotherapy is being used for the past five years either as first line or second line treatment with great results. Chemotherapy and radiotherapy have been also used as combination to immunotherapy to further enhance this type of treatment. Intratumoral treatment has been previously proposed as a treatment option for certain non-small cell lung cancer patients.

Patients and Methods: We recruited in total seventy four patients with non-small cell lung cancer in their second line treatment who received only chemotherapy in their first line treatment with programmed death-ligand-1 ≤ 50. Only adenocarcinoma or squamous cell carcinoma, and all negative for epidermal growth factor receptor, anaplastic lymphoma kinase, proto-oncogene tyrosine-protein kinase-1 and proto-oncogene B-Raf. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones. Twenty five received only intravenous immunotherapy and forty-nine intravenous cisplatin with immunotherapy. Data were first examined with descriptive statistics choosing frequencies for categorical variables and histograms for the continuous ones.

Results: The relationships between changes of performance status and disease progression were examined via a single correspondence analysis. The two-dimensional scores (coordinates) derived from the correspondence analysis were then regressed against the predictors to form distinct splits and nodes obtaining quantitative results. The best fit is usually achieved by lowering exhaustively the AICc criterion and looking in parallel the change of R2 expecting improvements more than 5%. both types of therapy are capable of producing best ameliorative effects, when either the programmed death-ligand-1 expression or parenchymal site in joint with low pack years are present in the sampling data.

Conclusions: Intratumoral treatment combination with cisplatin plus immunotherapy indifferent of nivolumab or pembrolizumab combination is an effective choice. In specific for those with endobronchial lesions. Moreover; patients with programmed death-ligand-1 ≥ 50 had their performance status and disease progression improved over the eight month observation.

Keywords: EBUS, non-small cell lung cancer, chemotherapy, immunotherapy, nivolumab, pembrolizumab, cisplatin.


Citation styles

APA
Zarogoulidis, P., Hohenforst-Schmidt, W., Huang, H., Zhou, J., Wang, Q., Wang, X., Xia, Y., Ding, Y., Bai, C., Kosmidis, C., Sapalidis, K., Sardeli, C., Tsakiridis, K., Zaric, B., Kovacevic, T., Stojsic, V., Sarcev, T., Bursac, D., Kukic, B., Baka, S., Athanasiou, E., Hatzibougias, D., Michalopoulou-Manoloutsiou, E., Petanidis, S., Drougas, D., Drevelegas, K., Paliouras, D., Barbetakis, N., Vagionas, A., Freitag, L., Lallas, A., Boukovinas, I., Petridis, D., Ioannidis, A., Matthaios, D., Romanidis, K., Karapantzou, C. (2021). Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G. Journal of Cancer, 12(9), 2560-2569. https://doi.org/10.7150/jca.55322.

ACS
Zarogoulidis, P.; Hohenforst-Schmidt, W.; Huang, H.; Zhou, J.; Wang, Q.; Wang, X.; Xia, Y.; Ding, Y.; Bai, C.; Kosmidis, C.; Sapalidis, K.; Sardeli, C.; Tsakiridis, K.; Zaric, B.; Kovacevic, T.; Stojsic, V.; Sarcev, T.; Bursac, D.; Kukic, B.; Baka, S.; Athanasiou, E.; Hatzibougias, D.; Michalopoulou-Manoloutsiou, E.; Petanidis, S.; Drougas, D.; Drevelegas, K.; Paliouras, D.; Barbetakis, N.; Vagionas, A.; Freitag, L.; Lallas, A.; Boukovinas, I.; Petridis, D.; Ioannidis, A.; Matthaios, D.; Romanidis, K.; Karapantzou, C. Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G. J. Cancer 2021, 12 (9), 2560-2569. DOI: 10.7150/jca.55322.

NLM
Zarogoulidis P, Hohenforst-Schmidt W, Huang H, Zhou J, Wang Q, Wang X, Xia Y, Ding Y, Bai C, Kosmidis C, Sapalidis K, Sardeli C, Tsakiridis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Baka S, Athanasiou E, Hatzibougias D, Michalopoulou-Manoloutsiou E, Petanidis S, Drougas D, Drevelegas K, Paliouras D, Barbetakis N, Vagionas A, Freitag L, Lallas A, Boukovinas I, Petridis D, Ioannidis A, Matthaios D, Romanidis K, Karapantzou C. Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G. J Cancer 2021; 12(9):2560-2569. doi:10.7150/jca.55322. https://www.jcancer.org/v12p2560.htm

CSE
Zarogoulidis P, Hohenforst-Schmidt W, Huang H, Zhou J, Wang Q, Wang X, Xia Y, Ding Y, Bai C, Kosmidis C, Sapalidis K, Sardeli C, Tsakiridis K, Zaric B, Kovacevic T, Stojsic V, Sarcev T, Bursac D, Kukic B, Baka S, Athanasiou E, Hatzibougias D, Michalopoulou-Manoloutsiou E, Petanidis S, Drougas D, Drevelegas K, Paliouras D, Barbetakis N, Vagionas A, Freitag L, Lallas A, Boukovinas I, Petridis D, Ioannidis A, Matthaios D, Romanidis K, Karapantzou C. 2021. Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G. J Cancer. 12(9):2560-2569.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image